Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA NASDAQ:JAGX NASDAQ:NEUP NASDAQ:NRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.26$2.11$1.55▼$5.18$15.89M0.2736,577 shs13,136 shsJAGXJaguar Animal Health$2.22-0.4%$2.87$1.93▼$35.25$4.27M0.4398,457 shs48,867 shsNEUPNeuphoria Therapeutics$7.84+3.3%$7.30$2.12▼$12.55$14.27M0.5342,480 shs14,997 shsNRSNNeuroSense Therapeutics$1.34-2.9%$1.96$0.60▼$2.60$18.86M1.64357,210 shs382,037 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech+2.22%-0.66%+9.71%+4.63%-54.16%JAGXJaguar Animal Health-0.45%+3.74%-12.60%-74.45%-92.34%NEUPNeuphoria Therapeutics+3.29%-3.92%+9.50%+58.70%+783,999,900.00%NRSNNeuroSense Therapeutics-2.90%-22.99%-35.89%+27.63%+98.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDSAEdesa Biotech1.3694 of 5 stars2.05.00.00.00.01.70.6JAGXJaguar Animal Health1.8414 of 5 stars3.53.00.00.01.10.00.6NEUPNeuphoria Therapeutics1.1797 of 5 stars3.50.00.00.00.00.00.6NRSNNeuroSense Therapeutics2.077 of 5 stars3.54.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 4.00Strong Buy$5.00121.24% UpsideJAGXJaguar Animal Health 3.00Buy$60.002,602.70% UpsideNEUPNeuphoria Therapeutics 3.00Buy$21.00167.86% UpsideNRSNNeuroSense Therapeutics 3.00Buy$14.00944.78% UpsideCurrent Analyst Ratings BreakdownLatest JAGX, NEUP, EDSA, and NRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.005/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AJAGXJaguar Animal Health$11.55M0.37N/AN/A$12.29 per share0.18NEUPNeuphoria Therapeutics$10K1,473.92N/AN/A$15.85 per share0.49NRSNNeuroSense TherapeuticsN/AN/AN/AN/A($0.04) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)NEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)NRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%9/29/2025 (Estimated)Latest JAGX, NEUP, EDSA, and NRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025JAGXJaguar Animal Health-$7.13N/AN/AN/A$3.27 millionN/A8/8/2025N/AEDSAEdesa Biotech-$0.23N/AN/AN/AN/AN/A5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A15.7215.72JAGXJaguar Animal Health22.201.080.70NEUPNeuphoria TherapeuticsN/A11.0111.01NRSNNeuroSense TherapeuticsN/A0.712.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%JAGXJaguar Animal Health12.04%NEUPNeuphoria Therapeutics15.90%NRSNNeuroSense Therapeutics1.04%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%JAGXJaguar Animal Health4.55%NEUPNeuphoria Therapeutics0.69%NRSNNeuroSense Therapeutics27.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.03 million5.44 millionNot OptionableJAGXJaguar Animal Health501.91 million1.83 millionNo DataNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ANRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableJAGX, NEUP, EDSA, and NRSN HeadlinesRecent News About These CompaniesNeuroSense Provides Business Update and Progress for the First Half of 2025August 1, 2025 | prnewswire.comAward-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and CommunityJuly 22, 2025 | prnewswire.comNeuroSense Therapeutics Releases Q2 2025 Corporate UpdateJuly 10, 2025 | tipranks.comNeurosense Therapeutics Ltd News (NRSN) - Investing.comJuly 2, 2025 | investing.comNeuroSense Completes Key Meeting with Health Canada for ALS Drug ApprovalJune 26, 2025 | tipranks.comTop Nasdaq Companies by Market Cap Ranked by KalkineJune 7, 2025 | kalkinemedia.comKNeurosense, awaiting Canada approval, scales PrimeC productionMay 15, 2025 | alsnewstoday.comAD. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy RecommendationMay 14, 2025 | msn.comWhy This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsMay 12, 2025 | benzinga.comNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchMay 7, 2025 | prnewswire.comNeuroSense Therapeutics Advances ALS Treatment and Strategic PartnershipApril 24, 2025 | tipranks.comNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdateApril 24, 2025 | prnewswire.comNeuroSense Therapeutics Presents Promising Phase 2b Data on PrimeC for ALS at AAN MeetingApril 10, 2025 | sohu.comSNeuroSense Therapeutics Reports Year-End 2024 Financial Results and Provides Business UpdatesApril 10, 2025 | sohu.comSNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentApril 9, 2025 | prnewswire.comNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesApril 7, 2025 | prnewswire.comNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingApril 4, 2025 | prnewswire.comMarket Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS DrugMarch 20, 2025 | businesswire.comNeuroSense Advances PrimeC Commercialization in CanadaMarch 19, 2025 | tipranks.comPESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment LandscapeMarch 17, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAGX, NEUP, EDSA, and NRSN Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.26 0.00 (0.00%) Closing price 08/6/2025 03:33 PM EasternExtended Trading$2.28 +0.02 (+0.71%) As of 08/6/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Jaguar Animal Health NASDAQ:JAGX$2.22 -0.01 (-0.45%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$2.22 0.00 (0.00%) As of 08/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Neuphoria Therapeutics NASDAQ:NEUP$7.84 +0.25 (+3.29%) As of 08/6/2025 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.NeuroSense Therapeutics NASDAQ:NRSN$1.34 -0.04 (-2.90%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$1.33 -0.01 (-0.75%) As of 08/6/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
